pharma · Bleeding Complication During Colon Polypectomy · Cancer of Colon
Yang Xiaotian
Yang Xiaotian is a pharma organization headquartered in CN. Primary therapeutic focus areas include Bleeding Complication During Colon Polypectomy, Cancer of Colon, Erosive Esophagitis, Gastric Cancer, Primary Aldosteron
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 5
- Drugs
- 2
- Patents
- 0
Ilaprazole
Approved · small molecule · Gastric Cancer
Ilaprazole for Gastric Cancer is a Approved program (small_molecule) at Yang Xiaotian with 1 ClinicalTrials.gov record(s).
Internal code HUMC-ILA01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Yang Xiaotian
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Gastric Cancer
- Status
- completed
- Trials
- 1